Group 1 - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for HW231019 tablets, aimed at evaluating its efficacy and safety for postoperative pain relief after abdominal surgery [1] - The trial is a multicenter, randomized, double-blind, parallel, placebo-controlled study, with the objective to explore the efficacy and safety of HW231019 tablets and to preliminarily investigate its dosage for postoperative pain [1] - HW231019 tablets received approval for clinical trials in March 2025 for the treatment of acute pain, and the cumulative R&D investment in this project has reached approximately 20 million RMB [1] Group 2 - Currently, there is one company in the same target and type of drug for acute pain that has entered Phase II/III clinical stages, four companies in Phase II, and two companies in Phase I clinical stages [1] - The company emphasizes that drug registration requires completion of clinical trials and approval from the National Medical Products Administration before market launch, highlighting the lengthy and uncertain nature of drug development [2]

Core Viewpoint - The announcement indicates that the company’s subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for HW231019 tablets with the National Medical Products Administration [1] Group 1 - The company holds an 80% stake in Yichang Renfu Pharmaceutical Co., Ltd. [1] - The registration of the clinical trial is a significant step in the drug development process [1]

Core Viewpoint - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for HW231019 tablets, focusing on postoperative pain management and safety [1] Group 1: Clinical Trial Information - The Phase II clinical trial aims to explore the efficacy and safety of HW231019 tablets for pain relief after abdominal surgery [1] - The trial will also preliminarily investigate the dosage and administration of HW231019 tablets for postoperative pain management [1]

Core Viewpoint - The announcement indicates that Yichang Renfu, a subsidiary of Renfu Pharmaceutical, has registered the Phase II clinical trial information for HW231019 tablets, which are intended for postoperative pain relief following abdominal surgery [1] Group 1: Clinical Trial Information - HW231019 tablets are being studied in a multicenter, randomized, double-blind, parallel, placebo-controlled trial to evaluate their efficacy and safety [1] - The trial is registered on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 2: Research and Development Investment - Yichang Renfu has invested approximately 20 million RMB in the research and development of this project [1]